natgillin/translations-raw huggingface dataset:
LDL cholesterol is often called ‘bad’ cholesterol because it can build up in the walls of your arteries and form plaque.
LDL holesterol pogosto imenujemo "slabi" holesterol, ker se lahko kopiči v stenah arterij in tako povzroči nastanek leh.
LDL-C (%)
LDL-H (%)
LDL-C (ITT )a
LDL-H (ZNZ)a
LDL-C (ITT)a
LDL-H (ZNZ)a
LDL-C (on treatment)b
LDL-H (med zdravljenjem)b
LDL-C reduction was consistent regardless of concomitantly used statins and doses.
Znižanje LDL-H je bilo dosledno, ne glede na sočasno uporabljene statine in odmerke.
LDL-C values <25 mg/dL (<0.65 mmol/L)
Vrednosti LDL-H < 25 mg/dl (< 0,65 mmol/l)
LDLR is the primary receptor that clears circulating LDL, therefore the decrease in LDLR levels by PCSK9 results in higher blood levels of LDL-C.
LDLR je primarni receptor, ki odstranjuje LDL v obtoku, zato znižanje ravni LDLR zaradi PCSK9 zviša koncentracijo LDL-H v krvi.
LDPE BOTTLE 30 ml LABEL
NALEPKA NA STEKLENIČKI LDPE 30 ml
LDPE Syringe
LDPE brizga
Le Vet B.V. Wilgenweg 7
Wilgenweg 7
LE11 5SF, United Kingdom
LE11 5SF, Velika Britanija
LE11 5SF, United Kingdom
LE11 5SF, Združeno kraljestvo (Velika Britanija)
LE18 4YL, United Kingdom
LE18 4YL, Velika Britanija
LEAD POT
SVINČENA POSODA
LEAD POT
SVINČENI VSEBNIK
Lead the needle into the big outer needle cap without touching it.
Konico igle vstavite v veliki zunanji pokrovček igle, ne da bi se ga pri tem dotaknili.
Lead the needle tip into the outer needle cap on a flat surface without touching the needle or the outer cap.
Konico igle vstavite v zunanji pokrovček igle na ravni površini, ne da bi se dotaknili igle ali zunanjega pokrovčka igle.
Lead the needle tip into the outer needle cap on a flat surface without touching the needle or the outer needle cap.
Konico igle vstavite v zunanji pokrovček igle na ravni površini, ne da bi se dotaknili igle ali zunanjega pokrovčka igle.
Lead-In Response‡ (Viral Load Reduction)
Odziv med uvajalnim obdobjem‡ (zmanjšanj e virusnega bremena)
leading to a risk of rifamycin resistance and a treatment failure.
odpornosti proti rifamicinu in neuspeh zdravljenja.
leakage of the drug into the surrounding tissue at the site of injection, which may cause swelling or redness swelling of arms and/or legs
prepuščanje zdravila v okoliško tkivo na mestu injiciranja, kar lahko povzroči otekanje ali rdečino otekanje rok in/ali nog
leakage of the infusion to the surrounding tissue (extravasation), causing skin inflammation (infusion site dermatitis) and shedding (infusion site desquamation) or injection site ulcers tissue damage around tumours of the lymph system and complications due to swelling of such tumours
iztekanje infuzije v okoliško tkivo (ekstravazacija), ki povzroči vnetje kože (dermatitis na mestu infuzije) in luščenje (deskvamacija na mestu infuzije) ali razjede na mestu injiciranja poškodba tkiva okoli tumorja limfnega sistema in zapleti zaradi otekline takega tumorja
leakage of urine
uhajanje urina,
leaking from tiny blood vessels, rapid breathing, nosebleeds, breathing difficulties, breathlessness, cough;
krvavitve iz majhnih žil, hitro dihanje, krvavitve iz nosu, težave pri dihanju, zasoplost, kašelj;
leaking milk from the breasts in girls
izločanje mleka iz prsi pri dekletih
Learn to deal with diet-related treatment effects
Naučite se spoprijemati z neželenimi učinki
Learn to deal with diet-related treatment effects
Naučite se spoprijemati z neželenimiučinki
Learning how to use the pre-filled pens
Naučite se uporabljati napolnjene injekcijske peresnike
least 1 day, until healing is achieved.
najmanj en dan, dokler se ne
least 10% (%)
10 % (%)
least 2.0 ELISA U per doses
≥ 2,0 enot v testu ELISA na odmerek
least 24 to 48 hours before the chemotherapy and radiotherapy starts.
Zadnje tri odmerke pred kemoterapijo in radioterapijo morate dobiti vsaj 24 do 48 ur pred začetkom kemoterapije in radioterapije.
least 4.9 log 10 CCID50 per dose
CCID50 na odmerek Inaktivirani
Least Square Difference vs Placebo mITT Population: Study 016/018 - Placebo (n=212), safinamide 50 mg/day (n=217) and 100 mg/day (n=216), and SETTLE - Placebo (n=270), safinamide 50-100 mg/day (n=273).
Least Square Difference vs Placebo - razlika, izračunana po najmanjših kvadratov, v primerjavi s placebom populacija mITT : študija 016/018 - placebo (n = 212), safinamid 50 mg/dan (n = 217) in 100 mg/dan (n = 216) ter SETTLE - placebo (n = 270), safinamid 50-100 mg/dan (n = 273).
Least Square Means (SE)
Srednja vrednost po metodi najmanjših kvadratov (SE)
Leave a gap of at least 3 months after your last treatment before you start breast-feeding.
Preden ponovno začnete dojiti, mora od vašega zadnjega zdravljenja miniti vsaj 3 mesece.
Leave Avonex Pen to warm up
Počakajte, da se napolnjen injekcijski peresnik Avonex Pen ogreje.
Leave it at room temperature for half an hour.
Injekcijsko brizgo pustite pri sobni temperaturi pol ure.
Leave it to dry in the air - lay it on its side with the mouth-piece open.
Posušite ga na zraku – položite ga na bok z odprtim ustnikom.
Leave Plegridy to warm to room temperature before injecting.
Pred injiciranjem počakajte, da se zdravilo Plegridy ogreje na sobno temperaturo.
Leave the cartridge in the pen, put the cap on the pen, and store it in the refrigerator.
Vložek pustite v injekcijskem peresniku, ga zaprite z zaporko in shranite v hladilniku.
Leave the cartridge in the pen.
Vložek pustite v injekcijskem peresniku.
Leave the filter needle in the vial and disconnect the syringe from the filter needle.
Iglo s filtrom pustite v viali in z nje odstranite brizgo.
Leave the inner needle shield in position.
Notranji ščitnik igle pustite, kot je nameščen.
Leave the needle in the vial.
Iglo pustite v viali.
Leave the needle shield on the needle
Pokrovček pustite na igli.
Leave the needle under the skin for at least 6 seconds to make sure you get your full dose.
Pustite iglo pod kožo vsaj 6 sekund, da zagotovite injiciranje celotnega odmerka.
Leave the patch on your skin for 24 hours, then remove it and apply a new one.
Obliž pustite na koži 24 ur, nato ga odstranite in prilepite novega.
Leave the plunger rod untouched in the carton.
Nosilec bata pustite v škatli.
Leave the reconstitution needle and empty syringe in the vial.
Rekonstitucijsko iglo in prazno injekcijsko brizgo pustite v viali.
Leave the syringe at room temperature for approximately 30 minutes or hold the pre-filled syringe gently in your hand for a few minutes.
Pustite brizgo na sobni temperaturi približno 30 minut ali nežno držite napolnjeno brizgo v roki za nekaj minut.
Leave the syringe in place.
Brizgo pustite v viali.
Leave the syringe in the rubber stopper.
Brizgo pustite v gumijastem zamašku.
Leave the vial and syringe to stand for 15 minutes.
Vialo in brizgo pustite, da stojita 15 minut.
Leave the white needle cap in place and wait approximately 15-30 minutes to allow the Enbrel solution in the pen to reach room temperature.
Počakajte 15 do 30 minut, da se raztopina zdravila Enbrel v peresniku segreje na sobno temperaturo, beli pokrovček igle naj medtem ostane na mestu.
Leave them to stand for 5 minutes.
Pustite, da stojita 5 minut.
Leaving the sponges in the tray, UNIFORMLY distribute onto each sponge 1.4 ml dibotermin alfa solution as shown in the illustration (Figure 2).
ENAKOMERNO nanesite 1,4 ml raztopine dibotermina alfa (rhBMP-2) na vsako od obeh gobic kot je prikazano na spodnji shemi (Slika 2).
Lecithin Oleic acid
Lecitin Oleinska kislina
lecithin, simethicone, yellow iron oxide (E172).
šelak lecitin simetikon rumeni železov oksid (E172)
Ledipasvir (90 mg once daily)/
ledipasvir (90 mg enkrat
Ledipasvir and sofosbuvir are substrates of drug transporter P-gp and BCRP while GS-331007 is not.
Ledipasvir in sofosbuvir sta substrata prenašalca P-gp in BCRP, GS-331007 pa ni.
ledipasvir AUC 1.92 (1.77-2.07) ↑ ledipasvir Cmax 1.81 (1.69-2.94) ↑ ledipasvir Cmin not studied simeprevir AUC 2.69 (2.44-2.96) ↑ simeprevir Cmax 2.61 (2.34-2.86) ↑ simeprevir Cmin not studied
ledipasvir AUC 1,92 (1,77-2,07) ↑ ledipasvir Cmax 1,81 (1,69-2,94) ↑ ledipasvir Cmin niso preučevali simeprevir AUC 2,69 (2,44-2,96) ↑ simeprevir Cmax 2,61 (2,34-2,86) ↑ simeprevir Cmin niso preučevali
Ledipasvir AUC is dose proportional over the dose range of 3 to 100 mg.
Vrednost AUC za ledipasvir je sorazmerna z odmerkom v razponu odmerka od 3 do 100 mg.
Ledipasvir is a HCV inhibitor targeting the HCV NS5A protein, which is essential for both RNA
Ledipasvir je zaviralec HCV, ki deluje na beljakovino HCV NS5A, ki je bistvena za replikacijo RNA
Ledipasvir is an in vitro inhibitor of drug transporter P-gp and breast cancer resistance protein (BCRP) and may increase intestinal absorption of co-administered substrates for these transporters.
Ledipasvir je in vitro zaviralec prenašalca P-gp in proteina rezistence pri raku dojke (BCRP-breast cancer resistance protein) in lahko poveča absorpcijo sočasno uporabljenih substratov za te prenašalce v črevesju.
Ledipasvir/Sofosbuvir (90 mg/400 mg once daily)/ Emtricitabine/Rilpivirine/ Tenofovir disoproxil fumarate (200 mg/25 mg/300 mg once daily)
(90 mg/400 mg enkrat dnevno)/ emtricitabin/rilpivirin/ dizoproksiltenofovirijev fumarat (200 mg/25 mg/300 mg enkrat dnevno)
Ledipasvir/Sofosbuvir (90 mg/400 mg once daily)/ Rilpivirine
ledipasvir/sofosbuvir (90 mg/400 mg enkrat dnevno)/rilpivirin
Ledipasvir/Sofosbuvir (90 mg/400 mg once daily)/ Tenofovir alafenamide
ledipasvir/sofosbuvir (90 mg/400 mg enkrat dnevno)/alafenamidtenofovirat
Ledipasvir/Sofosbuvir (90 mg/400 mg q.d.) +
didanozin/dizoproksiltenofovirijev
Ledipasvir/Sofosbuvir (90 mg/400 mg q.d.) +
ledipasvir/sofosbuvir
Ledipasvir/Sofosbuvir (90 mg/400 mg q.d.) + Efavirenz/Emtricitabine/Tenofovir disoproxil fumarate (600 mg/200 mg/300 mg q.d.)
ledipasvir/sofosbuvir (90 mg/400 mg enkrat dnevno) + efavirenz/emtricitabin/ dizoproksiltenofovirijev fumarat (600 mg/200 mg/300 mg enkrat dnevno)
Ledipasvir/Sofosbuvir (90 mg/400 mg q.d.) + Efavirenz/Emtricitabine/Tenofovir disoproxil fumarate (600 mg/200 mg/300 mg q.d.)
ledipasvir/sofosbuvir (90 mg/400 mg enkrat dnevno) + efavirenz/emtricitabin/ dizoproksiltenofovirijev fumarat (600 mg/200 mg/300 mg enkrat dnevno.)
Ledipasvir/Sofosbuvir (90 mg/400 mg q.d.) + Emtricitabine/Rilpivirine/ Tenofovir disoproxil fumarate (200 mg/25 mg/300 mg q.d.)
ledipasvir/sofosbuvir (90 mg/400 mg enkrat dnevno) + emtricitabin/rilpivirin/ dizoproksiltenofovirijev fumarat (200 mg/25 mg/300 mg enkrat dnevno)
Ledipasvir/Sofosbuvir (90 mg/400 mg q.d.) + Emtricitabine/Rilpivirine/Tenofovir disoproxil fumarate (200 mg/25 mg/300 mg q.d.)
ledipasvir/sofosbuvir (90 mg/400 mg enkrat dnevno) + emtricitabin/rilpivirin/ dizoproksiltenofovirijev fumarat (200 mg/25 mg/300 mg enkrat dnevno)
Ledipasvir:
ledipasvirja/sofosbuvirja in
Ledipasvir:
sofosbuvir:
Ledipasvir: AUC: ↑ 78%
ledipasvir: AUC: ↑ 78
leep apnoea syndrome (stopping breathing for short periods while asleep)
če imate apnejo v spanju (t.j. če med spanjem večkrat prenehate dihati za kratek čas)
leep apnoea syndrome, hyperventilation, pneumonia aspiration, respiratory tract
indrom apneje v spanju, hiperventilacija, aspiracijska pljučnica, kongestija dihal, disfonija
leep apnoea syndrome, hyperventilation, pneumonia aspiration, respiratory tract congestion, dysphonia
indrom apneje v spanju, hiperventilacija, aspiracijska pljučnica, kongestija dihal, disfonija
leep apnoea syndrome, pulmonary congestion, respiratory tract
indrom apneje v spanju, pljučna kongestija, kongestija dihalnih poti, piskajoče
leep disorder
motnja spanja
leep disorder
motnje spanja
leep disorder
motnje spanja,
leep disorder,
otopelostc
leep disorder, confusion, decreased sexual drive, inability to reach orgasm, nervousness, nightmares tardive dyskinesia (twitching or jerking movements that you cannot control in your face, tongue, or other parts of your body).
motnje spanja, zmedenost, zmanjšana spolna sla, nezmožnost doseganja orgazma, živčnost, nočne more tardivna diskinezija (nenadzorovano trzanje ali sunkoviti gibi, ki jih ne morete nadzorovati, na obrazu, jeziku ali drugih delih telesa).
leep disorder, confusional state, libido decreased, anorgasmia, nervousness, nightmare
motnje spanja, zmedenost, zmanjšan libido, anorgazmija, živčnost, nočne more
leep disorder, decreased sexual drive, nervousness, nightmares
motnje spanja, zmanjšana spolna sla, nervoznost, nočne more
leep disorder, elated mood (mania), confusion, decreased sexual drive, nervousness, nightmares tardive dyskinesia (twitching or jerking movements that you cannot control in your face, tongue, or other parts of your body).
motnje spanja, stanje vznesenosti (manija), zmedenost, zmanjšana spolna sla, živčnost, nočne more tardivna diskinezija (nenadzorovano trzanje ali sunkoviti gibi, ki jih ne morete nadzorovati, na obrazu, jeziku ali drugih delih telesa.
leep disorder, libido decreased, nervousness, nightmare
motnje spanja, zmanjšan libido, nervoznost, nočne more
leep disorder, mania, confusional state, libido decreased, nervousness, nightmare
motnje spanja, manija, zmedenost, zmanjšan libido, živčnost, nočne more
leep disorders
motnje spanja
leep disorders (abnormal sleeping);
motnje spanja (nenormalno spanje);
leep disorders including inability to get adequate sleep
motnje spanja, vključno z nezmožnostjo, da bi se zadostno naspal,
leep disorders, abnormal drowsiness, confusion, depression, anxiety, agitation
motnje spanja, neobičajna zaspanost, zmedenost, depresija, tesnoba, nemir
leep disturbances
motnje spanja
leep disturbances including nightmares
motnje spanja, vključno z nočnimi morami,
leep interruptions
motnje spanja
leep interruptions;
motnje spanja;
leep problems
težave s spanjem,
leep problems, feeling anxious, emotional instability, or mood swings
težave s spanjem, občutek zaskrbljenosti, čustvena nestabilnost ali menjava razpoloženja,
leep problems, feeling anxious, emotional instability, or mood swings
težave s spanjem, občutek zaskrbljenosti, čustvena nestabilnost ali menjava razpoloženja;
leep problems, somnolence,
težave s spanjem, somnolenca,
leep-inducing, prevention of seizures
pomoč pri spanju, preprečevanje epileptičnih napadov
leepiness
zaspanost
leepiness
zaspanost,
leepiness (somnolence)
zaspanost (solmolenca)
leepiness (somnolence)
zaspanost (somnolenca)
leepiness (somnolence)  neck pain
zaspanost (somnolenca)  bolečina v vratu
leepiness abnormal taste.
zaspanost nenormalen občutek za okušanje
leepiness hot flushes
navali vročine
leepiness hot flushes
zaspanost navali vročine
leepiness or drowsiness fever (temperature 38°C or higher) pain, redness, swelling at the injection site
zaspanost ali dremavost, vročina (38 °C ali več), bolečina, pordelost ali oteklina na mestu injiciranja.
leepiness or trouble sleeping
zaspanost ali nespečnost
leepiness,
zaspanost,
leepiness, dizziness, bone pain, breast pain, muscle pain, leg cramps or swelling, general swelling, inflammation of the retina (the light-detecting membrane of the eye), increased tear production, blurred vision, feeling of pins and needles or pain in hands and feet;
zaspanost, omotica, bolečine v kosteh, dojkah in mišicah,mišični krči v nogah ali otekanje nog, splošno otekanje, vnetje očesne mrežnice (očesna ovojnica, s katero zaznavamo svetlobo), povečano solzenje, zamegljen vid, mravljinčenje ali bolečine v dlaneh ali stopalih
leepiness, dizziness, headache
zaspanost, omotica, glavobol
leepiness, dizziness, headache
zaspanost, omotica, glavobol,
leepiness, drowsy
zaspanost, dremavost,
leepiness, falling asleep suddenly without warning, difficulty in sleeping, sleep problems, having unusual dreams
zaspanost, nenaden spanec brez opozorila, nespečnost, motnje spanja, nenavadne sanje
leepiness, sedation, excessive tiredness, weakness, migraine, numbness, swelling of arms or legs, drug withdrawal syndrome (may manifest by the occurrence of the following side effects nausea, vomiting, diarrhoea, anxiety, chills, tremor, and sweating), shaking, falls, chills
zaspanost, sediranost, izjemna utrujenost, slabost, migrena, otopelost, oteklost nog ali rok, odtegnitveni sindrom, (lahko se kaže s pojavom naslednjim neželenih učinkov: siljenje na bruhanje, bruhanje, driska, tesnoba, mrzlica, tremor in znojenje) tresenje, padci, mrzlice
leepiness, tiredness, light-headedness and less frequently confusion,
zaspanost, utrujenost, vrtoglavica in redkeje zmedenost
leepiness;
zaspanost;
leeping more than normal (hypersomnia)
pite več, kot je normalno (hipersomnija),
leeping pills (e.g. alprazolam, zolpidem) and also midazolam administered by injection;
uspavala (npr. alprazolam, zolpidem) in tudi midazolam, ki se daje z injekcijo;
leeping pills (e.g. alprazolam, zolpidem) and also midazolam administered by injection;
uspavalne tablete (npr. alprazolam, zolpidem), tudi midazolam, ki ga dobite v injekciji;
leeplessness
nespečnost
leeplessness (insomnia), depression
nespečnost (insomnia), depresija
leeplessness (insomnia), depression
nespečnost (insomnijo), depresija,
leeplessness (insomnia), depression
nespečnost (insomnijo), depresijo,
leeplessness enlargement of the male breast
nespečnost povečanje moških prsi
Leflunomide does this by blocking an enzyme called ‘dihydroorotate dehydrogenase’, which is necessary for the lymphocytes to multiply.
Leflunomid deluje tako, da zavira encim, imenovan dihidroorotat dehidrogenaza, ki je potreben za razmnoževanje limfocitov.
Leflunomide does this by blocking an enzyme called ‘dihydroorotate dehydrogenase’, which is necessary for the lymphocytes to multiply.
Leflunomid deluje tako, da zavira encim, imenovan „dihidroorotat dehidrogenaza“, ki je potreben za delitev limfocitov.
Leflunomide does this by blocking an enzyme called ‘dihydroorotate dehydrogenase’, which is necessary for the lymphocytes to multiply.
Leflunomid to doseže z zaviranjem encima, imenovanega „dihidroorotat- dehidrogenaza“, ki je potreben za razmnoževanje limfocitov.
Leflunomide is effective in animal models of arthritis and of otherautoimmune diseases and transplantation, mainly if administered during the sensit isation phase.
Leflunomid je učinkovit v živalskih modelih artritisa, drugih avtoimunskih bolezni in presaditev, predvsem če je uporabljen med senzibilizacijsko fazo.
Leflunomide is indicated for the treatment of adult patients with active rheumatoid arthritis as a "disease-modifying antirheumatic drug" (DMARD), active psoriatic arthritis.
Leflunomid je indiciran za zdravljenje odraslih bolnikov z aktivnim revmatoidnim artritisom kot imunomodulirajoče antirevmatično zdravilo ("disease-modifying antirheumatic drug" (DMARD)), aktivnim psoriatičnim artritisom.
Leflunomide is indicated for the treatment of adult patients with: active rheumatoid arthritis as a "disease-modifying antirheumatic drug" (DMARD), active psoriatic arthritis.
Leflunomid je indiciran za zdravljenje odraslih bolnikov z: aktivnim revmatoidnim artritisom kot imunomodulirajoče antirevmatično zdravilo ("disease- modifying antirheumatic drug" (DMARD)), aktivnim psoriatičnim artritisom.
Leflunomide is indicated for the treatment of adult patients with: active rheumatoid arthritis as a "disease-modifying antirheumatic drug" (DMARD), active psoriatic arthritis.
Leflunomid je indiciran za zdravljenje odraslih bolnikov z: aktivnim revmatoidnim artritisom kot imunomodulirajoče proirevmatično zdravilo ("disease- modifying antirheumatic drug" (DMARD)), aktivnim psoriatičnim artritisom.
Leflunomide is indicated for the treatment of adult patients with: active rheumatoid arthritis as a "disease-modifying antirheumatic drug" (DMARD), active psoriatic arthritis.
Leflunomid je indiciran za zdravljenje odraslih bolnikov z: aktivnim revmatoidnim artritisom kot imunomodulirajoče protirevmatično zdravilo ("disease- modifying antirheumatic drug" (DMARD)), aktivnim psoriatičnim artritisom.
Leflunomide is indicated for the treatment of adult patients with: active rheumatoid arthritis as a "disease-modifying antirheumatic drug" (DMARD). active psoriatic arthritis.
Leflunomid je indiciran za zdravljenje odraslih bolnikov z: aktivnim revmatoidnim artritisom kot imunomodulirajoče antirevmatično zdravilo ("disease- modifying antirheumatic drug" (DMARD)) aktivnim psoriatičnim artritisom.
Leflunomide is metabolised to one primary (A771726) and many minormetabolites including TFMA (4-trifluoromethylaniline).
Leflunomid se presnovi v en glavni (A771726) in več stranskih presnovkov, med katerimi je tudi TFMA (4-trifluorometilanilin).
Leflunomide is rapidly converted to theactivemetabolite, A771726, by first-pass metabolism (ring opening) in gut wall and liver.
Leflunomid se že med presnovo prvega prehoda v črevesni steni in jetrih hitro pretvori (z odprtjem obroča) v aktivni presnovek A771726.
Leflunomide medac
Leflunomid medac
Leflunomide medac 10 mg film-coated tablets
Leflunomid medac 10 mg filmsko obložene tablete
Leflunomide medac 10 mg film-coated tablets Leflunomide medac 15 mg film-coated tablets Leflunomide medac 20 mg film-coated tablets
Leflunomid medac 10 mg filmsko obložene tablete Leflunomid medac 15 mg filmsko obložene tablete Leflunomid medac 20 mg filmsko obložene tablete
Leflunomide medac 10 mg film-coated tablets: Pack sizes of 30, 60, 90 or 100 film-coated tablets per bottle are available.
Zdravilo Leflunomid medac 10 mg filmsko obložene tablete: na voljo so pakiranja s 30, 60, 90 ali 100 filmsko obloženimi tabletami na plastenko.
Leflunomide medac 15 mg film-coated tablets
Leflunomid medac 15 mg filmsko obložene tablete
Leflunomide medac 15 mg film-coated tablets are white to almost white and round with a diameter of about 7 mm.
Leflunomid medac 15 mg filmsko obložene tablete so bele do skoraj bele barve in okrogle oblike s premerom približno 7 mm.
Leflunomide medac 20 mg film-coated tablets
Leflunomid medac 20 mg filmsko obložene tablete
Leflunomide medac 20 mg film-coated tablets: Pack sizes of 15, 30, 60, 90 or 100 film-coated tablets per bottle are available.
Zdravilo Leflunomid medac 20 mg filmsko obložene tablete: na voljo so pakiranja s 15, 30, 60, 90 ali 100 filmsko obloženimi tabletami na plastenko.
Leflunomide medac can make you feel dizzy which may impair your ability to concentrate and react.
Zdravilo Leflunomid medac lahko povzroči omotičnost, kar lahko prizadene sposobnost za koncentracijo in reagiranje.
Leflunomide medac contains lactose
Zdravilo Leflunomid medac vsebuje laktozo.
Leflunomide medac is a ‘generic medicine’.
Leflunomide medac je „generično zdravilo“.
Leflunomide medac is notrecommended foruse in children and adolescents below 18 years of age .
Uporaba zdravila Leflunomid medac ni priporočljiva pri otrocih in mladostnikih, ki so mlajši od 18 let.
Leflunomide medac is used to treat adult patients with active rheumatoid arthritis or with active psoriatic arthrit is.
Zdravilo Leflunomid medac se uporablja za zdravljenje odraslih bolnikov z aktivnim revmatoidnim artritisom ali aktivnim psoriatičnim artritisom.
Leflunomide medac may be taken with or without food.
Zdravilo Leflunomid medac lahko jemljete s hrano ali brez nje.
Leflunomide medac treatment usually starts with a ‘loading dose’ of 100 mg once a day for three days, followed by a maintenance dose.
Zdravljenje z zdravilom Leflunomide medac se običajno začne z „udarnim odmerkom“ v višini 100 mg enkrat na dan tri dni zapored, čemur sledi vzdrževalni odmerek.
Leflunomide medac with food, drink and alcohol
Zdravilo Leflunomid medac skupaj s hrano, pijačo in alkoholom
Leflunomide ratiopharm contains lactose
Zdravilo Leflunomid ratiopharm vsebuje laktozo.
Leflunomide ratiopharm is a ‘generic medicine’.
Leflunomide ratiopharm je „generično zdravilo“.
Leflunomide ratiopharm is contraindicated in pregnancy (see section 4.3).
Zdravilo Leflunomid ratiopharm je kontraindicirano med nosečnostjo (glejte poglavje 4.3).
Leflunomide ratiopharm treatment starts with a ‘loading dose’ of 100 mg once a day for three days, followed by a maintenance dose.
Zdravljenje z zdravilom Leflunomide ratiopharm se začne z „udarnim odmerkom“ 100 mg enkrat na dan tri dni zapored, čemur sledi jemanje vzdrževalnega odmerka.
Leflunomide Teva 10 mg film-coated tablets
Leflunomid Teva 10 mg filmsko obložene tablete
Leflunomide Teva 10 mg film-coated tablets are white, round film-coated tablets, engraved with “10” on one side and “L” on the other.
Leflunomid Teva 10 mg filmsko obložene tablete so bele, okrogle filmsko obložene tablete, z vgravirano oznako »10« na eni strani in »L« na drugi strani.